Clinical trials of BRAF/MEK inhibition for brain metastases have shown clinical utility.25 The COMBI-MB trial (NCT02039947) demonstrated that dabrafenib (BRAF inhibitor) plus trametinib (MEK1/2 inhibitor) has activity in patients with BRAF V600-mutant melanoma brain metastases and a manageable safety profile. Here, MAP2K7 is linked to melanoma.